Background: ADP-ribosylation factors (ARFs) have been shown to activate phospholipase D (PLD), an enzyme modulated by extracellular signals, including several growth factors and, in particular, insulin. We have tested the hypothesis that ARF proteins are involved specifically in insulin-induced activation of PLD.
Background
ADP-ribosylation factors (ARFs) activate phospholipase D (PLD) in the presence of GTP analogues in vitro [1] . PLD catalyzes hydrolysis of phosphatidylcholine to phosphatidic acid and choline, and is activated by a number of growth factors, including insulin [2] [3] [4] [5] [6] [7] [8] . But although support is mounting for the idea that ARF proteins may play an important role in the signal transduction mechanisms by which growth factors, cytokines and hormones modulate PLD activity, no evidence of the activation of ARF by tyrosine kinase receptors has been reported to date.
Two mammalian PLD genes, PLD1 and PLD2, have been cloned recently [9] [10] [11] . The product of one of these genes, PLD1, is regulated by small GTP-binding proteins and protein kinase C [9, 10] . Plasma membrane preparations reportedly contain a PLD activity that is significantly stimulated by ARF and Rho [12, 13] , but the relationship of this PLD activity to PLD1 or PLD2 has not been established. There is as yet relatively little information on the mechanism of activation of Rho and ARF proteins by extracellular signals. A few recent reports have suggested that ARF proteins may be activated by cell surface receptors [14] [15] [16] , and several ARF guanine-nucleotide exchange factors have been described recently, some of which appear to be recruited to the cell membrane via pleckstrin homology domains [17, 18] . A direct demonstration of receptor-mediated activation of ARF proteins is still lacking, however. Furthermore, there is no evidence of the involvement of ARF in the activation of PLD by receptor tyrosine kinases.
Recently, Karnam et al. [19] suggested that translocation of ARF and Rho to the plasma membrane can be stimulated by insulin in rat adipocytes. One of their major conclusions was that Rho is activated by insulin and that this process plays an important role in the modulation of PLD activity by insulin; the activation of ARF was not examined, however. Here, we have investigated the involvement of ARF proteins in the insulin-mediated activation of PLD. The rationale of the approach was that stimulation of cells with insulin should activate ARF proteins if ARF proteins are involved in insulin-mediated PLD activation; also, depletion of ARF should inhibit insulin-induced activation of PLD; and addition of ARF proteins to ARF-depleted cells should reconstitute insulin-sensitive PLD activity.
We have addressed these issues using a model system consisting of Rat-1-fibroblast-derived cell lines that overexpress either wild-type human insulin receptors (HIRcB cells) or mutated, tyrosine-kinase-deficient human insulin receptors (A/K1018 cells) [20, 21] . We report here that insulin stimulates PLD activity in HIRcB cells, and that this process is mediated by ARF proteins. We also show that insulin-treated HIRcB cell membranes and partially purified receptors obtained from these cells can activate ARF proteins in vitro. Finally, we have examined the mechanism of activation of ARF by the insulin receptor. Our data show that macromolecular complexes are formed at the membrane involving the insulin receptor, ARF and perhaps additional adaptor proteins.
Results

Binding of GTP␥S to ARF is activated by insulin-treated cell membranes
We examined the activation of purified bovine ARF by HIRcB cell membrane preparations using a reconstitution assay similar to that described by Randazzo et al. [22] . In these experiments, a purified bovine ARF preparation was incubated with membranes that had either been treated with insulin in the presence of ATP or left untreated. Insulin-treated HIRcB cell membranes stimulated the binding of GTP␥[ 35 S] to purified bovine ARF ( Fig. 1 shows data obtained with bovine brain ARF; very similar results were obtained with recombinant, myristoylated human ARF1). The observed rates of GTP␥S binding to ARF in the presence of insulin-treated membranes are comparable to those previously reported using ARF and purified Golgi membranes in similar reconstitution systems [22] [23] [24] . Figure 1b shows the amount of GTP␥S bound after a 30 minute incubation of cell membranes with or without ARF under the conditions indicated. The data were analyzed by analysis of variance (ANOVA) followed by pairwise post-test comparisons using a Bonferroni test. Although the cell membranes alone appeared to have a small effect on binding of GTP␥S to ARF, this was not statistically significant. Insulin pretreatment of the membranes increased the binding of GTP␥S to ARF-reconstituted cell membranes significantly (p < 0.01), but not the binding of GTP␥S to membranes alone. This effect was completely abolished by brefeldin A (BFA), a fungal metabolite that blocks ARF activation by Golgi membranes [22] [23] [24] .
The effects of insulin on the activation of ARF were studied, using membranes obtained from A/K1018 cells that express a human insulin receptor which is mutated at the ATP-binding site and lacks tyrosine kinase activity (Fig. 1c) . Neither insulin-treated nor naive, untreated A/K1018 membranes were able to stimulate binding of Activation of purified bovine ARF by membranes from HIRcB and A/K1018 cells. HIRcB cell membranes (10 g) were treated as follows: boiled membranes were incubated at 100°C for 5 min; insulintreated membranes were incubated with insulin (100 nM), ATP (1 mM) and MgCl 2 (3 mM) for 10 min; BFA-treated membranes were incubated with BFA for 5 min prior to any subsequent treatment. GTP␥S to ARF under the conditions of the reconstitution assay. Thus, the effects of insulin on the activation of ARF by membranes require a receptor with an intact, functional ATP-binding site. Although ATP and Mg 2+ were included in all assays shown in Figure 1 , we do not believe that the activation of ARF required the tyrosine kinase activity of the receptor: in some experiments, the non-hydrolyzable ATP analogue AMPPCP was used instead of ATP and identical results were observed (data not shown).
Insulin and GTP␥S promote the binding of ARF proteins to cell membranes
The data described above show that ARF can be activated by cell membranes in an insulin-dependent manner. An additional approach was used to confirm these initial observations. Activated (GTP-bound) ARF proteins are membrane-bound, whereas the GDP-bound form of these proteins is cytosolic. Thus, ARF-GDP complexes leak out of cells after treatment with digitonin (a cell-membrane permeabilizing agent), whereas ARF-GTP complexes do not [15] . Figure 2 shows that simultaneous treatment with insulin and GTP␥S prevented the leakage of ARF from digitonin-treated cells. HIRcB cells were serum starved and treated with digitonin in the presence or absence of insulin and GTP␥S, and the presence of ARF in the supernatants and cell pellets was determined by immunoblotting. Untreated cells did not release ARF, whereas digitonintreated cells released a large fraction of their ARF content, which appeared as a prominent band in the supernatant sample. Cells treated with digitonin in the presence of GTP␥S released a slightly smaller fraction of ARF. Addition of insulin during digitonin treatment had no effect.
However, the release of ARF from cells treated with digitonin in the presence of both insulin and GTP␥S was negligible, with almost all ARF remaining in the pellet sample. Thus, treatment with insulin and GTP␥S induces binding of ARF to cell membranes.
The effects of GTP␥S alone on binding of ARF to membranes were significantly less obvious than those reported by others [15, 16, 25] . A major difference between our assay and those reported previously is that we used cells that were serum-starved for about 20 hours to obtain proper baseline levels for ARF and PLD activity, whereas the others used membranes or permeabilized cells that had not been subjected to prolonged serum starvation. In order to address this issue experimentally, the effects of insulin on PLD activity and ARF translocation were examined in cells that had not been serum starved and were compared to the effects observed in serum-starved cells. Consistent with our explanation, GTP␥S alone was sufficient to promote significant binding of ARF to membranes and PLD activity in cells that had not been serum starved, regardless of the presence of insulin (data not shown). Figure 3 demonstrates that insulin activates PLD in HIRcB cells ( Fig. 3a) and that ARF proteins are likely to be involved in this process (Fig. 3b,c) . HIRcB cells were treated with digitonin under the same conditions described for Figure 2 . PLD activity paralleled the ARF release results (compare Figs 2 and 3 ). Insulin and GTP␥S had a significant effect on PLD activity only when both were included in the permeabilization medium. Cells treated with digitonin in the absence of GTP␥S and insulin (conditions in which macromolecules such as ARF may leak out of the cell as shown in Fig. 2 ) lost their ability to respond to insulin and GTP␥S added after permeabilization. These observations demonstrate that the combined effects of insulin and GTP␥S on the activation of PLD require soluble factors that are removed during permeabilization with digitonin; they do not prove, however, that the missing factor(s) are ARF proteins. Nevertheless, as shown in Figure 3c , the addition of recombinant ARF to these cytoplasm-depleted cells reconstituted the sensitivity of PLD to insulin and GTP␥S. Recombinant ARF and GTP␥S together had no significant effects on PLD activity in the absence of insulin. The activation of PLD by the insulin signalling system therefore requires GTP␥S and soluble cytosolic factors, and in addition, ARF alone is sufficient to restore insulin-and GTP␥S-sensitive PLD activity in cytosol-depleted HIRcB cells. These observations were made in serum-starved cells: as stated above, insulin had no effects in cells that had not been previously serum starved.
ARF proteins mediate insulin-induced PLD activation
A recent report has suggested that activation of PLD by insulin in rat adipocytes is likely to be mediated by Rho
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Figure 2
Insulin stimulates the binding of ARF to cell membranes in digitonintreated HIRcB fibroblasts. After serum starvation, HIRcB cells were gently scraped, resuspended in PBS and permeabilized with digitonin (Dig; 8 M) where indicated. GTP␥S (100 M) and/or insulin (Ins; 100 nM) were included in the permeabilization buffer for some samples, as indicated. After incubation at 37°C for 10 or 20 min, the cells were centrifuged for 15 min in a microcentrifuge. Supernatants and pellets were collected, resolved by SDS-PAGE and electroblotted. ARF was detected using the monoclonal antibody 1D9, followed by chemiluminescence. proteins [19] . This was based primarily on the effects of Clostridium botulinus exotoxin C3, a bacterial toxin that catalyzes the ADP-ribosylation of Rho and appears to prevent its interaction with downstream effectors. We failed to detect any effects of exotoxin C3 on the activation of PLD by insulin in intact HIRcB fibroblasts (data not shown). In marked contrast, BFA, which acts primarily as an inhibitor of ARF activation, completely blocked the effects of insulin on the activation of PLD (Fig. 4) . The effects of BFA were acute and 10 minute incubations with the inhibitor were sufficient to cause complete inhibition of PLD activity. In contrast, the studies of Karnam et al. [19] involved treatment with C3 exotoxin for at least 3 hours. These results suggest that ARF, rather than Rho, is the principal mediator of the activation of PLD by insulin in HIRcB cells.
The insulin receptor forms a complex with ARF proteins
We have shown that insulin induces activation of PLD by a mechanism that involves activation of ARF proteins. We thus decided to examine more closely the mechanism by which the insulin receptor activates ARF. A hallmark of the mechanism of most tyrosine kinase receptors is the formation of macromolecular complexes comprising the receptor, adaptor and target proteins. Hence, we examined the formation of macromolecular complexes involving the insulin receptor and ARF proteins. Initially, the insulin receptors of HIRcB cells were immunoprecipitated either with 83-7, a monoclonal antibody that specifically recognizes the ␣ subunit of the human insulin receptor [26] , or with insulin immobilized in agarose. We looked for putative guaninenucleotide binding proteins in the immunoprecipitate using azido-␥[ 32 P]-GTP, a universal detection reagent which , recombinant hARF1 (rhARF1; 6 g ml -1 ) or a combination of these agents as indicated. Data in (a) were analyzed by Student's t test, whereas data in (b,c) were analyzed by ANOVA followed by Bonferroni post-test pairwise comparisons to the respective control groups. All experiments were repeated at least three times.
Figure 4
Brefeldin A inhibits the activation of phospholipase D by insulin. Cells were serum starved and pre-labelled with [ 3 H]-palmitate as described in Materials and methods and incubated with BFA at the concentrations indicated for 10 min before the addition of insulin. PLD activity was determined as described in the legend to efficiently labels small and heterotrimeric G proteins and is crosslinked to these proteins on irradiation with ultraviolet light. Although we occasionally found a single 32 To further examine the nature of the GTP-binding proteins coimmunoprecipitated with the insulin receptor, the solubilized receptor was bound to immobilized monoclonal antibody 83-7 and the bound material analyzed by SDS-PAGE. Proteins were blotted onto nitrocellulose and the resulting blots probed with the monoclonal antibody CT-1, which recognizes the carboxyl terminus of the ␤ subunit of the insulin receptor [26] , as an internal control of the efficiency of the immunoprecipitation procedure. Blots were also probed with the following anti-GTP-binding protein antibodies: Y13-259 and Y13-238 (both of which recognize Ras proteins); commercially available antibodies specific for RhoA and RhoB; and a specific anti-ARF antibody, 1D9 [27] . Only the anti-ARF antibody showed any immunoreactivity against the material coprecipitated with the receptor (Fig. 6 ; negative results are not shown). These findings demonstrate that ARF coimmunoprecipitates with the insulin receptor whereas Ras and Rho proteins do not.
Coimmunoprecipitation of ARF with the insulin receptor was greatly enhanced by addition of insulin to the solubilization and immunoprecipitation buffers (Fig. 6a) . Stimulation of the cells with insulin before solubilization had relatively little effect on the efficiency of the coimmunoprecipitation of ARF with the receptor from the HIRcB cell lysates and the effects of insulin were observed only when the hormone was present during both solubilization and immunoprecipitation. This suggests that the interactions of ARF with the insulin receptor complex are reversible, such that the complex dissociates on prolonged incubation in the absence of insulin. We also examined insulin receptors precipitated with insulin-agarose from HIRcB cell lysates (Fig. 6b) . Controls for the experiments shown in Figure 6b were obtained by addition of 10 M free insulin to the affinity binding reaction. Free insulin prevented both binding of the insulin receptor to the affinity agarose beads and precipitation of ARF. This leads us to conclude that the presence of ARF in the material coprecipitated with the insulin receptor using either monoclonal antibody 83-7 or immobilized insulin is the result of specific interactions of ARF with either the insulin receptor or a protein associated with it. ARF could not be detected in the insulin-agarose-precipitated tyrosine kinase-defective receptors obtained from A/K1018 cell lysates (Fig. 6c) , suggesting that, consistent with the observations from studies performed using A/K1018 cell membranes, A/K1018 receptors are not coupled to ARF proteins.
A common feature of most activators of GTP-binding proteins is that they bind preferentially to the nucleotidefree form of their targets [28] [29] [30] . Thus, activators are known to decrease the affinity of GTP-binding proteins for guanine nucleotides and, conversely, guanine nucleotides reduce the affinity of GTP-binding proteins for their respective activators. Figure 6d shows that, when guanine nucleotides were included in the solubilization and affinity binding buffers, insulin receptors precipitated with insulin-agarose failed to coprecipitate ARF proteins. This suggests that guanine nucleotides significantly reduce the affinity of ARF for the insulin receptor complex and, therefore, that the coprecipitation of ARF with the insulin receptor is probably the result of the interaction of ARF with a specific nucleotide exchange factor.
Activation of recombinant human ARF1 by immunoprecipitated insulin receptors
An immunoprecipitation assay developed by Buday and Downward [31] to study Ras activation in vitro was adapted to prove that an ARF nucleotide exchange factor was present in the insulin receptor immune complexes. We studied the binding of GTP␥S to recombinant human ARF1 (rhARF1) in the presence or absence of insulin receptor immunoprecipitates. When insulin was omitted from the immunoprecipitation buffer, the purified receptors had no effect on the binding of GTP␥S to rhARF1, regardless of whether insulin was present in the GTP␥S binding buffer (Fig. 7a) . However, receptors immunoprecipitated in the presence of insulin had a remarkable stimulatory effect on the rate of binding of GTP␥S to rhARF (Fig. 7b) . These results suggest that the insulin receptor does not stimulate the activation of ARF directly and that a third component, which shows enhanced binding to the insulin receptor in the presence of insulin, is the actual stimulator of GTP␥S binding. However, we cannot rule out at this time the possibility that the presence of insulin might protect the solubilized insulin receptor from partial denaturation during the immunoprecipitation procedure.
Discussion
The discovery that ARF proteins activate PLD in vitro has generated some speculation about the actual role of ARF in receptor-mediated PLD regulation. ARF proteins have been associated with both vesicle transport within the Golgi complex and between the endoplasmic reticulum and Golgi complex [32] , as well as with endosome fusion [33] , receptor-mediated endocytosis [34] and several other processes related to intracellular membrane transport. With the exception of ARF6, which is permanently bound to the Investigation of the GTP-binding proteins coimmunoprecipitated with the insulin receptor. Cell lysates were precipitated with monoclonal antibody 83-7 or insulin-agarose as indicated, and electroblotted onto nitrocellulose filters. The upper half of each blot was developed with the monoclonal antibody CT-1 (which recognizes the ␤ subunit of the insulin receptor) detecting the 95 kDa band; the lower half of each blot was developed with the anti-ARF antibody 1D9, which detects the 19 kDa species. Whole cell lysates and material bound to the immobilized insulin resin in the presence of excess free insulin were included as controls. (a) Insulin enhances the association of ARF with the insulin receptor. The control immunoprecipitation from HIRcB lysates was carried out using 10 g non-immune mouse IgG. The other immunoprecipitations used the monoclonal antibody 83-7(2 g) with or without insulin (100 nM). These experiments were repeated independently four times. plasma membrane, ARF proteins have been found either dispersed in the cytosol or associated with Golgi membranes [34] [35] [36] . A link between ARF activation and receptor signalling has therefore been difficult to conceptualize and very little attention has been paid to the potential role of ARF proteins in the processing of extracellular signals.
Our data strongly suggest that there is a functional relationship between the insulin receptor and the activation of ARF proteins which results in the stimulation of PLD. We show that the binding of GTP␥S to ARF is stimulated by insulin-treated membranes at levels that are comparable to those reported for stimulation by Golgi membranes [22] [23] [24] . We also show that, as for Golgi membranes, activation of ARF by insulin-treated membranes is BFA-sensitive. Furthermore, activation of ARF proteins by insulin-treated membranes requires a functional insulin receptor: tyrosinekinase negative receptor mutants fail to catalyze the binding of GTP␥S to ARF. We also show that ARF is required for insulin-mediated PLD activation. Thus, our data are consistent with a role for ARF proteins in specific signalling mechanisms. Finally, our data suggest that ARF interacts with the insulin receptor, either directly or via an unknown adaptor protein, thus suggesting a mechanism by which the insulin receptor, and perhaps other related receptor tyrosine kinases, may regulate PLD activity.
An intriguing aspect of our studies is that activation of ARF by the insulin receptor does not require ATP hydrolysis. Non-hydrolyzable ATP analogues could substitute for ATP in all assays performed, and ATP was not required for activation of ARF or PLD in digitonin-treated (permeabilized) cells. In contrast, mutant A/K1018 insulin receptors failed to interact with ARF proteins in reconstitution or immunoprecipitation assays. These mutants have no tyrosine kinase activity because lysine 1018 is replaced by an alanine. As K1018 is one of the critical amino acids of the ATP-binding site of the ␤ subunit of the receptor [20] , A/K1018 mutants not only lack tyrosine kinase activity but also exhibit very little affinity for ATP. Our data suggest that activation of ARF proteins and PLD by insulin receptors requires an intact ATP-binding site but does not require autophosphorylation or tyrosine kinase activity.
A second interesting aspect of our studies using digitonintreated cells is that short incubations with GTP␥S alone did not promote binding of ARF to membrane and the combination of GTP␥S and recombinant ARF was not sufficient to restore the PLD activity of ARF-depleted cell pellets. These observations were repeated many times with invariable results. However, our data appear to contradict some previous reports which indicate that GTP␥S promotes binding of ARF to membranes [16, 25] and that recombinant ARF and GTP␥S alone are sufficient to reconstitute PLD activity [1, 9, 16] . The explanation for these discrepancies appears to be related to different experimental conditions: for instance, all our experiments were carried out using cells, or membranes from cells, that had been serum-starved for 20 hours, whereas none of the reports cited above showed data from serum-starved cells. During prolonged serum starvation, the levels of some of the endogenous activators of ARF or PLD, such as PIP 2 , associated with the Golgi complex and other cell compartments might be reduced. To investigate whether the observed differences might be related to whether the cells had been subjected to prolonged serum starvation, we determined PLD activity and ARF membrane-binding in cells that had not been serum starved. Our observations showed that in the absence of serum starvation basal PLD activity is high and that it is not stimulated by insulin; in addition, insulin is no longer required to promote the binding of ARF to membranes or to activate PLD in the presence of GTP␥S and recombinant ARF in permeabilized cells (data not shown).
There are multiple mammalian ARF genes and so specific functions for different members of the family can be envisioned. ARF6 is the only ARF that has been found at the plasma membrane and would thus be a prime candidate to play a significant role in receptor signalling [34, 36] . However, a specific anti-ARF6 antibody (a gift of P. Stahl) failed to bind to the ARF protein that coprecipitated with the insulin receptor in our experiments (data not shown), although control experiments demonstrated that ARF6 is abundantly expressed in HIRcB cells. Thus, ARF6 does not appear to be the major ARF protein associated with the insulin receptor in HIRcB cells. Furthermore, our reconstitution experiments demonstrate that recombinant human ARF1 can substitute for endogenous ARF proteins in insulin-dependent PLD activation. Therefore, ARF proteins other than ARF6 are likely to be involved in insulin receptor-dependent PLD regulation.
Many questions remain to be addressed regarding the nature of the interactions of the insulin receptor and ARF. As insulin is required for the formation of complexes that include the insulin receptor and ARF proteins, it is apparent that the insulin receptors that interact with ARF are either in the plasma membrane or in early endocytic vesicles formed shortly after insulin binding. These views are supported by the recent data of Karnam et al. [19] who have shown that, in adipocytes, insulin induces a three-fold increase in the amount of ARF bound to the plasma membrane with no significant changes in the levels of ARF bound to a microsomal fraction. Furthermore, our data suggest that the interaction of ARF with the receptor is not direct and that a putative ARF GDP-exchange factor (GEF) might be involved. The nature of this putative GEF remains to be determined, but in view of the recent findings that cytohesin-1 is a GEF for ARF [18] that can be recruited to the plasma membrane by integrins [37] , we speculate that the putative GEF recruited by the insulin receptor is a member of the cytohesin family.
Are both ARF and Rho proteins involved in insulinmediated activation of PLD? Current evidence seems to indicate that there are at least two redundant pathways by which insulin might activate PLD. One of these involves the activation of RhoA and phosphoinositide 3′-kinase [19] , and is probably mediated by the tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1). The second pathway involves ARF proteins but does not appear to require the tyrosine kinase activity of the insulin receptor. Figure 8 illustrates a working model for the activation of PLD by insulin through these two parallel pathways.
Finally, the issue of the specific roles played by ARF in insulin signalling remains open. ARF (and possibly PLD) functions are mainly related to the modulation of processes that involve membrane transport. There are at least two membrane transport processes that are finely regulated by insulin: the internalization of the insulin receptor and the recruitment of glucose transporters to the surface of the cell, both of which are inhibited by BFA, a potent blocker of the activation of ARF [38, 39] . These studies therefore support the view that ARF-mediated signalling pathways may play an important role in insulin function.
Conclusions
We have investigated the mechanism of activation of PLD by insulin using fibroblasts that overexpress the insulin receptor as a model system. We have shown that insulin activates PLD and ARF proteins in cells that express wild-type insulin receptors, but not in cells that express receptors mutated at the ATP-binding site; that ARF proteins can mediate the effects of insulin on PLD activation; and that ARF proteins form macromolecular complexes with the insulin receptor by a mechanism that is activated by insulin, inhibited by guanine nucleotides and apparently requires the presence of specific adaptor proteins. A simple model that accounts for our observations is the following. Upon binding insulin, the insulin receptor may form a complex with ARF proteins, probably via the recruitment of an ARF activator (ARF-GEF). Upon binding to the receptor complex, the affinity of ARF for guanine nucleotides decreases, allowing the dissociation of GDP from ARF and the replacement of GDP with GTP. As ARF-GTP spontaneously binds to cell membranes, activated ARF-GTP complexes bind to intracellular membranes where they modulate several processes, such as the activation of PLD.
Materials and methods
Cell culture
HIRcB and A/K1018 cells were cultured in 100 or 60 mm dishes using DMEM/F12 supplemented with 10% foetal bovine serum and 100 nM methotrexate, as described [38] . Cells were used within 3 days of subculture and were serum starved for 20 h in medium containing 0.1% BSA before treatment.
Membrane preparations
Cell membranes were prepared from ten 100 mm dishes of confluent cells. Cells were washed in phosphate-buffered saline (PBS), scraped, pelleted by centrifugation, resuspended in 50 mM Hepes (pH 7.6), 8% sucrose, 10 mM EDTA, 10 mM EGTA and 1 mM PMSF and disrupted using a glass homogenizer. Cell extracts were layered onto a 41% sucrose cushion (in Hepes buffer) and centrifuged for 90 min at 95 000 × g for 90 min. Membrane material at the interface was collected, diluted to 10 ml and centrifuged at 60 000 × g for 60 min. The membrane pellet was resuspended in 50 mM Hepes, diluted to about 1 mg ml -1 protein, aliquoted, and stored at -70 0 C until ready to use. This membrane preparation is relatively crude and may contain a significant amount of Golgi membranes.
ARF activation assays
ARF activation was studied by determining the binding of GTP␥S to purified bovine brain ARF or recombinant human ARF1. Bovine ARF was purified by a procedure essentially identical to that described by Kahn and Gilman [40] . The ARF protein preparation was further examined by SDS-PAGE and the presence of contaminant G proteins was examined by crosslinking an aliquot of the material to azido-␥[ 32 P]GTP followed by SDS-PAGE. Recombinant wild-type human ARF1 was purified from E. coli that coexpressed the ARF1 gene and yeast N-myristoyl transferase (a gift of R. Kahn). Enriched plasma membranes were prepared from confluent HIRcB and A/K1018 cells as described above. ARF (4-8g) and membranes (10 g) were incubated with GTP␥[ 35 S] (1 M, 34 mCi mol -1 ) at 37 0 C in 20 mM Hepes (pH 7.4)/100 mM NaCl/2 mM MgCl 2 /0.1% Na cholate/1 mM ATP (200 l final volume). At the indicated times, 50 l aliquots were collected and the reaction was quenched by the addition of 2 ml ice-cold stop buffer (same as above but containing 10 mM MgCl 2 and 100 M GTP␥S) and protein-bound nucleotide was separated by filtration through nitrocellulose filters. Bound nucleotide was determined by scintillation counting. Nonspecific binding was determined using excess unlabelled GTP␥S.
Immunoprecipitation and affinity binding assays
The following antibodies were used in these experiments: 83-7, a monoclonal antibody that recognizes specifically the ␣ subunit of the human insulin receptor; CT-1, a monoclonal antibody that recognizes the carboxyl terminus of the ␤ subunit of the insulin receptor ( [26] ; both of these were gifts of Peter Isakson, Monsanto). Cells from between one and three 100 mm plates were washed with cold PBS, scraped, centrifuged at 1 000 r.p.m. for 5 min in ice-cold PBS and solubilized in 1 ml 50 mM Hepes pH 7.4 containing 0.1 M NaCl, 1.5% sodium cholate, 1 mM EDTA, 1 mM EGTA, 5 g ml -1 leupeptin, 1 mM PMSF and 1 mg ml -1 soybean trypsin inhibitor. After solubilization for 1 h on ice, insoluble material was removed by centrifugation in a microfuge for 20 min. Insulin receptors were immunoprecipitated by incubation of aliquots of the cell lysate (about 1 mg of cell protein) with anti-mouse IgG agarose that had previously been equilibrated with 2-10 g of monoclonal antibody 83-7. Affinity purification assays were carried out using insulin-agarose (Sigma). In these experiments, 50 l of a 50% slurry of the insulin-agarose gel were washed with solubilization buffer (see above) and solubilized cell extracts and were used instead of the antibody-agarose complexes. Immunoprecipitations and affinity precipitations were carried out overnight at 4 0 C or for 2 h at room temperature.
Immunoprecipitates were washed twice with immunoprecipitation buffer, twice with immunoprecipitation buffer containing 0.1% cholate and once with cholate-free immunoprecipitation buffer. Control immunoprecipitations were carried out using non-immune mouse IgG. Negative controls for the affinity-precipitation of the receptor were carried out in the presence of a large excess (10 M) of free insulin. In some of the experiments, the effects of additional specific agents such as insulin (immunoprecipitations only, 100 nM), ATP (1 mM), AMPPCP (1 mM), GTP␥S (100 M) or GDP (1 mM) were tested. In all cases, these agents were included in the cell solubilization and immunoprecipitation buffer.
Immunoblotting
Protein bands resolved by SDS-PAGE were transferred to nitrocellulose filters. Filters were then cut in half horizontally. The upper part was used to detect the ␤ subunit of the insulin receptor; the lower half was used to detect ARF and other small GTP-binding proteins. The filters were blocked overnight at 4 0 C in blocking buffer (PBS containing 5% non-fat milk, 0.01% azide and 0.1% Tween). ARF was detected with 2 g ml -1 affinity purified 1D9 (a monoclonal antibody that recognizes most members of the ARF family [27] ; a gift of R. Kahn). Other antibodies used were: monoclonal anti-Ras antibodies Y13-238 and Y13-259 (affinity purified from hybridoma culture supernatants, a gift of S. Sebti), anti-RhoA and anti-RhoB polyclonals (Santa Cruz Biotechnology). The ␤ subunit of the insulin receptor was detected with the monoclonal antibody CT-1 (1 g ml -1 ). Bound antibodies were detected by chemiluminescence.
PLD activity assays
Cells (100 mm plates; 70-80% confluent) were serum starved and labelled overnight with 3 H-palmitate (5 Ci ml -1 ) in DMEM/F12. Cells were stimulated with insulin (100 or 200 nM) in the presence of 0.3% butanol for 20 min. The reaction was stopped by addition of chloroform:methanol (1:1). The lipid phase was extracted and developed by thin layer chromatography (TLC) on silica gel 60 plates using ethyl acetate:trimethylpentane:acetic acid (9:5:2) as the solvent. The position of major phospholipids was determined using true standards (Avanti Biochemicals) and autoradiography. The TLC plates were scraped and the total amount of radioactivity associated to each lipid species was determined by liquid scintillation counting. The data are expressed as the number of counts associated to the phosphatidylbutanol spot normalized by the total number of counts of lipid.
Digitonin treatment
HIRcB cells were serum starved, scraped gently, resuspended in PBS and treated with 8 M digitonin in the presence or absence of insulin (100 nM) and/or GTP␥S (100 M) at 37 0 C for 20 min. Magnesium (2 mM) and ATP or AMPPCP (2 mM) were included in some of the experiments. To release intracellular proteins, digitonin-treated cells were centrifuged in a microfuge for up to 15 min. PLD activity was determined using cells that had been labelled overnight with 3 H-palmitate (see above). Supernatants and pellets were collected separately and resolved by SDS-PAGE. ARF proteins were detected by immunoblotting as described above. PLD activity of the permeabilized cells was determined as described above.
Crosslinking experiments
Immunoprecipitated receptors were incubated with azido-␥[ 32 P]-GTP (7.5 M, 9.4 Ci mmol -1 ) for 20 min on ice in immunoprecipitation buffer (50 mM Hepes, pH 7.4, 0.1 M NaCl) containing 2 mM MgCl 2 . Where indicated, the reaction mix contained GTPS (200 M) or AMPPCP (1 mM). The immunoprecipitated material was incubated with azido-GTP for 15 min on ice in the dark to allow binding of the nucleotide to the immunoprecipitated proteins. Nucleotide was crosslinked to the protein by a 10 min exposure of the reaction mix to ultraviolet light using a hand held UV lamp. The protein was denatured by incubation with Laemmli buffer at 60 0 C for 10 min and resolved by SDS-PAGE in 12.5% acrylamide gels. Gels were dried and exposed to X-ray film for 24-72 h. On some occasions, proteins were transferred to nitrocellulose membranes before exposure to the X-ray film, as this procedure significantly reduced the background and generated cleaner results.
